Author: Breye Therapeutics

Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

September 23, 2026
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

February 11, 2026

Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine